Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Maintenance vs Continuation in mCRC (BLOC-1)
NCT02942706Phase 3Unknown
- Sponsor
- Ruijin Hospital
- Start
- Nov 2021
- Primary completion
- Oct 2022
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
A Phase 3 trial of cetuximab in metastatic colorectal cancer (mCRC), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT02942706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02942706.